Key result
Mefenamic acid and DIDS activate the IKs channel by binding to a common extracellular pocket formed by KCNE1 and KCNQ1 subunits, stabilizing the open state and slowing deactivation.
Why the study?
One group of chemical IKs activators requires the accessory KCNE1 subunit to be active, but the mechanism of this phenomenon was not fully understood.
This study maps the binding pocket for IKs activators, providing a mechanistic explanation for their action and a foundation for designing future therapeutics for IKs loss-of-function disorders.
May enable KCNE1-selective I Ks activation for loss-of-function syndromes; leaves clinical translation open pending further study.
The cardiac I Ks ion channel comprises KCNQ1, calmodulin, and KCNE1 in a dodecameric complex which provides a repolarizing current reserve at higher heart rates and protects from arrhythmia syndromes that cause fainting and sudden death. Pharmacological activators of I Ks are therefore of interest both scientifically and therapeutically for treatment of I Ks loss-of-function disorders. One group of chemical activators are only active in the presence of the accessory KCNE1 subunit and here we investigate this phenomenon using molecular modeling techniques and mutagenesis scanning in mammalian cells. A generalized activator binding pocket is formed extracellularly by KCNE1, the domain-swapped S1 helices of one KCNQ1 subunit and the pore/turret region made up of two other KCNQ1 subunits. A few residues, including K41, A44 and Y46 in KCNE1, W323 in the KCNQ1 pore, and Y148 in the KCNQ1 S1 domain, appear critical for the binding of structurally diverse molecules, but in addition, molecular modeling studies suggest that induced fit by structurally different molecules underlies the generalized nature of the binding pocket. Activation of I Ks is enhanced by stabilization of the KCNQ1-S1/KCNE1/pore complex, which ultimately slows deactivation of the current, and promotes outward current summation at higher pulse rates. Our results provide a mechanistic explanation of enhanced I Ks currents by these activator compounds and provide a map for future design of more potent therapeutically useful molecules.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2023) studied IKs channel function. Mefenamic acid and DIDS vs. Control (absence of drug) was evaluated on Shift in voltage of half-maximal activation (V1/2). Mefenamic acid and DIDS activate the IKs channel by binding to a common extracellular pocket formed by KCNE1 and KCNQ1 subunits, stabilizing the open state and slowing deactivation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: